Decidua Stromal Cells for Treatment of Steroid-Refractory Graft-Versus-Host Disease

  • سال انتشار: 1397
  • محل انتشار: سومین جشنواره ملی و کنگره بین المللی علوم و فناوری های سلول های بنیادی و پزشکی بازساختی
  • کد COI اختصاصی: NSCMRMED03_089
  • زبان مقاله: انگلیسی
  • تعداد مشاهده: 402
دانلود فایل این مقاله

نویسندگان

Behnam Sadeghi

Translational Cell Therapy Research Group (TCR), Division of Therapeutic Immunology, Department of LabMed, KarolinskaInstitutet, Stockholm, Sweden

Abbas Hajiftahi

Hematopoietic Stem Cell research center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Elham Roshandel

Hematopoietic Stem Cell research center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

چکیده

Graft-versus-host disease (GvHD) is a life-threatening complication anda major cause of morbidity and mortality after allogeneic hematopoieticcell transplantation (HSCT). Steroid refractory aGvHD is associatedwith a high mortality rate (up to 80%) despite intensified treatment withother immunosuppressive agents. Placenta-derived decidua stromalcells (DSCs) are a novel therapy for acute GvHD after allogeneic HSCT.DSCs are different from bone marrow and adipose-derived mesenchymalstromal cells in terms of immunosuppressive capacity and some othercharacteristics. To investigate the therapeutic potential of DSCs, thesecells isolated from the term placenta. Nine patients with steroid-refractoryGvHD (2 patients SOS and GvHD) and 1 patient with chronic GvHDreceived DSCs. The dose of infused cells for all of the patients was 1 × 106DSCs/kg. The patients were given 3 (1-8) doses, with a total of 34 infusions.GvHD response in patients as no, partial and complete was 3/2/5respectively. No adverse events related to the treatment were observedin patients. About 1 year after DSC therapy 4 patients were alive. Causesof death in patients were an infection (despite complete response in GI,skin and liver) due to treatment with monoclonal antibodies, sinusoidalobstruction syndrome (SOS) and liver dysfunction. In conclusion, DSCscan be an acceptable treatment for patients with steroid-refractory acuteGvHD and administered safely in these complicated patients but moreprospective clinical trials are needed.

کلیدواژه ها

Decidua stromal cells; Graft-versus-host disease; Hematopoietic stem cell transplantation

مقالات مرتبط جدید

اطلاعات بیشتر در مورد COI

COI مخفف عبارت CIVILICA Object Identifier به معنی شناسه سیویلیکا برای اسناد است. COI کدی است که مطابق محل انتشار، به مقالات کنفرانسها و ژورنالهای داخل کشور به هنگام نمایه سازی بر روی پایگاه استنادی سیویلیکا اختصاص می یابد.

کد COI به مفهوم کد ملی اسناد نمایه شده در سیویلیکا است و کدی یکتا و ثابت است و به همین دلیل همواره قابلیت استناد و پیگیری دارد.